In male rats continually self-administering nicotine (approximately 1.5 mg free base/kg/day), we found a significant increase of nicotinic acetylcholine receptors (nAChRs) labeled by epibatidine (Epb) in 11 brain areas. A large increase of highaffinity Epb binding sites was apparent in the ventral tegmentum/substantia nigra, nucleus tractus solitarii, nucleus accumbens, thalamus/subthalamus, parietal cortex, hypothalamus, and amygdala. A smaller but significant up-regulation of highaffinity Epb sites was seen in the piriform cortex, hippocampus, caudate/putamen, and cerebellar cortex. The up-regulation of nAChRs, shown by immunoadsorption and Western blotting, involved ␣4, ␣6, and ␤2 subunits. As a consequence of longterm self-administration of nicotine, the ␣6 immunoreactive (IR) binding of either labeled Epb or 125 I-␣-conotoxin MII increased to a much greater extent than did ␣4 or ␤2 IR binding of Epb. In addition, the ␤2 IR binding of Epb was consistently enhanced to a greater extent than was ␣4. These findings may reflect a larger surface membrane retention of ␣6-containing and, to some degree, ␤2-containing nAChRs compared with ␣4-containing nAChRs during long-term self-administration of nicotine.
involved ␣4, ␣6, and ␤2 subunits. As a consequence of longterm self-administration of nicotine, the ␣6 immunoreactive (IR) binding of either labeled Epb or 125 I-␣-conotoxin MII increased to a much greater extent than did ␣4 or ␤2 IR binding of Epb. In addition, the ␤2 IR binding of Epb was consistently enhanced to a greater extent than was ␣4. These findings may reflect a larger surface membrane retention of ␣6-containing and, to some degree, ␤2-containing nAChRs compared with ␣4-containing nAChRs during long-term self-administration of nicotine.
Nicotine, one of the most widely abused addictive alkaloids, activates a family of pentameric nicotinic acetylcholine receptors (nAChRs) known to transport cations. This affects the release of neurotransmitters (Gallardo and Leslie, 1998; Fu et al., 2000a) and influences diverse functions, including feeding, arousal, endocrine regulation, nociception, and aspects of cognition. Cell membrane nAChRs accumulate in various paradigms of long-term exposure to nicotine or other nAChR modulators. This occurs in the central nervous system of primates, including humans (Perry et al., 1999) ; of rodents, including mice (Marks et al., 1983; Pauly et al., 1996) and rats (Schwartz and Kellar, 1983; Mugnaini et al., 2002) ; as well as in mammalian cells expressing cloned nAChRs (Wang et al., 1998) .
No substantial up-regulation of mRNAs encoding the major nAChR subunits was detected in the brains of rodents that exhibited major increases in nAChRs after long-term treatment with nicotine (Pauly et al., 1996; Mugnaini et al., 2002) . The increases in nAChRs are thus not likely to depend primarily on enhanced de novo synthesis, but they could be linked to nAChR desensitization. A largely reversible partial desensitization of nAChRs in response to nicotine was documented in rodent brain (Damsma et al., 1989; Sharp and Matta, 1993) . In view of the low nAChR endocytosis and recycling in homeotherms (Higgins and Berg, 1988) and the generally limited control of concentration of cell membrane constituents, aggregation or compartmentalization of nAChRs could lead to the accumulation of membrane receptors during long-term nicotine treatment.
In rodent forebrain, the principal nAChRs contain ␤2 subunits (␤2* nAChRs) and ␣4 subunits (␣4* nAChRs) (Flores et al., 1992) ; ␣7 receptors are also well represented (Kaiser and Wonnacott, 2000) . In several areas, there is significant expression of ␣6* (Champtiaux et al., 2002; Zoli et al., 2002) and ␣3* (Azam et al., 2002) nAChRs. The release of dopamine by nicotine (Damsma et al., 1989; Fu et al., 2000a) seems to be associated with ␣6* (Champtiaux et al., 2002) , ␣3* (Kulak et al., 2001) , and ␣7 receptors (Fu et al., 2000b) . Indeed, nicotine-induced locomotor activity, associated with enhanced striatal dopaminergic activity, is selectively decreased by ␣6* antisense oligonucleotides (Le Novere et al., 1999) . Because the regulation of dopaminergic neurotransmission by acetylcholine may involve ␣6* receptors at the level of dopamine terminals (Champtiaux et al., 2003) , an increase in this subtype of nAChR during long-term exposure to nicotine may alter dopamine release.
In cell lines, up-regulation of surface nAChRs by nicotine was shown to include both ␣3* (Meyer et al., 2001; Ridley et al., 2002) and ␣6*, as well as ␣4* (Nelson et al., 2003) and ␣7 receptors (Quik et al., 1996) . Oocyte-expressed ␣3* receptors are less sensitive than the ␣4* receptors to down-regulation (Fenster et al., 1997) and desensitization (Hsu et al., 1996) by nicotinic agonists. This may also pertain to ␣6* receptors, because ␣3 and ␣6 subunits are structurally and pharmacologically similar (Champtiaux et al., 2002; Kulak et al., 2002) . Also, ␣4* receptors may show a larger constitutive removal from cell membrane than ␣3* receptors (Cooper et al., 1999) and presumably ␣6* receptors. Thus, nAChRs containing different ␣ subunits may not increase proportionally during long-term treatment with nicotine.
In view of the above findings, our experimental objectives were (1) to measure changes in nAChR expression related to long-term nicotine self-administration, especially in brain areas known for important interactions between nicotinic cholinergic and catecholaminergic neurotransmission and (2) to determine whether nicotine self-administration selectively up-regulates the nAChR subunits that are preferentially involved in the activation of catecholaminergic systems. Our results show a larger up-regulation of ␣6* (and also of ␤2*) relative to ␣4* nAChRs in several major brain areas of rats continually self-administering nicotine.
Materials and Methods
Chemicals and Antibodies. Chemicals were obtained from Sigma Chemical (St. Louis, MO) and Sigma/RBI (Natick, MA). Radioactive chemicals were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). ␣-Conotoxin MII was synthesized and labeled with 125 I by J. M. McIntosh. Mouse monoclonal antibody to bacterially expressed human ␣6 nAChR subunit (mAb350) and rat monoclonal antibodies against rat ␣4 (mAb299) and ␤2 (mAb295) subunits were raised by J. Luo and J. M. Lindstrom. To remove any ␣3 antibody-like immunoprotein, mAb350 was pretreated with human ␣3 nAChR subunit immobilized on CH Sepharose 4B (Kuryatov et al., 2000) . This antibody does not cross-react with ␣4␤2 or ␣3␤2 nAChRs expressed in oocytes (Kuryatov et al., 2000) . The polyclonal rabbit antibodies to bacterially expressed human ␣3 (sc-5590), ␣4 (sc-5591), ␣7 (sc-5544), and ␤2 (sc-11372) subunits were purchased from Santa Cruz Biochemicals (Santa Cruz, CA). These antibodies were all raised against large (Ն100 residues) C-terminal peptides from the respective subunits, and specific blocking peptides are not available. However, neither the monoclonal ␣6 antibody nor the polyclonal ␣4 and ␤2 antibodies produced significant immunoadsorption of ␣3␤4 nAChRs expressed in HEK-293 cells (Xiao et al., 1998) (see Results) . Also, saturating quantities of the polyclonal ␣7 antibody did not affect the immunoadsorption of any of the above antibodies; conversely, the immunoadsorption of 125 I-␣-bungarotoxin bound to solubilized ␣7 receptors from four brain areas was not modified by saturating amounts of the above ␣3, ␣4, ␣6, or ␤2 antibodies (see Results).
Animals and Treatments. Male Lewis rats (2.5 months of age; initial body weight, 220-240 g) were obtained from Harlan (Indianapolis, IN), and male DBA mice (6-7 weeks old) were from the National Cancer Institute (Bethesda, MD). All treatments were in accord with the animal care protocols approved by the Animal Care and Use Committee of the University of Tennessee Health Science Center at Memphis. Nicotine self-administration was performed according to our protocols published previously (Fu et al., 2001) . Briefly, 7 d after acclimation to a reverse-light cycle and handling, all rats received jugular cannulae under xylazine-ketamine anesthesia and then were immediately housed in individual environmental enclosures without shaping, conditioning, or food deprivation. After an additional 3 d of recovery, rats were randomly assigned to treatment groups, and the jugular lines were filled either with nicotine bitartrate (4 mM in heparinized saline; 50 l delivered over 0.81 s per 300 g of body weight in one self-administration) or saline without nicotine. The self-administration of nicotine proceeded as detailed previously (Fu et al., 2001) . Stable nicotine self-administration, defined as 3 consecutive days showing more than 40 active lever presses per day at less than 15% variance, and with active (green-lit) lever-press counts significantly greater than those of inactive lever, was achieved within 6.5 Ϯ 1.0 (mean Ϯ S.E.M.) days. At that time, the approximate dosage of self-administered nicotine free base was 1.5 mg/kg/day (Fig. 1 ). After 18 days of self-administration, the animals were anesthetized with isoflurane before decapitation by guillotine. Brains were promptly excised and frozen in dry ice before storage for not more than 14 days at Ϫ80°C.
Tissue Collection. The rat or mouse forebrains were sliced (at Ϫ7°C) into 1-mm thick sections. Selected areas were then excised according to the coordinates of Paxinos and Watson (1986) and Franklin and Paxinos (1997) , respectively. The following areas were collected from rat brains: parietal cortex, the piriform/entorhinal cortex, the caudate/putamen (from 0 to 2 mm anterior to bregma), nucleus accumbens (2 mm centered about anterior commissure and 0-2 mm anterior to bregma), amygdala (medial to entorhinal/piriform cortex, from approximately 3 to 6 mm posterior to bregma), hypothalamus (from optic chiasm to mammillary nuclei, 1-5 mm posterior to bregma), thalamus (including subthalamic area; approximately 2-3 mm inferior to corpus callosum and 3 mm lateral to midline, 1-6 mm posterior to bregma), hippocampus (from 4 to 6 mm posterior to bregma), ventral tegmental area/substantia nigra (VTA/ SN; ventral horizontal cut, 4-6 mm posterior to bregma), the nucleus tractus solitarii area (1 mm inferior and 2 mm lateral to the fourth ventricle, 11-13 mm posterior to bregma), and rostral cerebellar cortex. With mouse brains, the thalamus/subthalamus was collected from 0.5 to 3 mm posterior to bregma, 1 to 2 mm inferior to corpus callosum, and approximately 2.5 mm lateral to midline. The hippocampus was taken from 3 to 4 mm posterior to bregma, and parietal/somatosensory cortex at Ϯ1 mm from bregma. Excised tissues were immediately stored at Ϫ80°C and then processed to obtain particulates within 7 days.
Isolation of Particulates. The isolation of particulates was done at 0 to 4°C, essentially as described previously by Marks et al. (1998) . The tissue homogenate was made in ice-cold Epb assay buffer, using a motor-driven Teflon pestle at 800 rpm. The homogenate was sedimented for 12 min at 20,000g max , and the pellets were resedimented before storage at Ϫ80°C.
The Epibatidine Binding Assay. The protocol described by Marks et al. (1998) 3, 6, 10, 20, 30, 45, 60, and 90 min. In kinetic as well as in some saturation experiments, the binding was terminated by filtration using Whatman GF/C filters (Whatman, Clifton, NJ) (presoaked in 0.3% polyethylenimine) and washing with ice-cold assay buffer. No consistent differences in binding were apparent between the centrifugation and filtration protocols. The competition and most saturation assays were terminated by spinning for 12 min at 20,000g max at 4°C followed by rinsing with ice-cold assay buffer. The tube bottoms or filters containing bound 125 I-Epb were counted in a MicroMedic ␥-scintillation counter (Valeant Pharmaceuticals International, Costa Mesa, CA). For counting of [ 3 H]Epb, the pellets were solubilized, or the filters were soaked overnight in 2% sodium dodecylsulfate/10 mM Tris-HCl, pH 8.8, followed by the addition of liquid scintillation solvent and then underwent counting in a Beckman LS-3801 counter (Beckman Coulter, Fullerton, CA). Receptors solubilized in 2% Triton X-100 were quantified by polyethylene glycol precipitation (Parker et al., 1998b) .
The Binding of 125 I-Labeled ␣-Conotoxin MII and ␣-Bungarotoxin. ␣-Conotoxin MII (Cntx) was synthesized and monoiodinated (specific activity, 2170 Ci/mmol) as described previously (Whiteaker et al., 2000b) , and 125 I-labeled ␣-bungarotoxin (Bgtx) (specific activity, 140 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences. Assay inputs of Cntx and Bgtx were 0.4 and 1.0 nM, respectively. Nonspecific binding for Cntx was defined at 10 M (Ϫ)-cytisine plus 100 M (Ϫ)-nicotine (because nicotine alone in some cases did not displace all binding that was sensitive to cytisine). For Bgtx, nonspecific binding was defined at 1 M unlabeled Bgtx. The particulates were resedimented once from the binding buffer described by Whiteaker et al. (2000b) before incubation at 0.4 mg protein/ml protein for 2 (Cntx) and 5 (Bgtx) h at 24°C. The assay was terminated using Whatman GF/C filters presoaked in 1% polyethylenimine and rapid washing with ice-cold binding buffer. Nonspecific binding of Cntx and Bgtx was 40 to 60% of total binding.
Immunoadsorption of Nicotinic Receptors. At 2% Triton X-100 with inputs of solubilized protein lower than 0.2 mg/ml, the polyclonal rabbit antibodies to C-terminal portions of human ␣3, ␣4, and ␤2 nAChR subunits (expressed in Escherichia coli) produced saturating immunoadsorption of Epb-labeled nAChRs at immunoglobulin concentrations lower than 6 g/ml; the mouse and rat monoclonal antibodies produced saturating immunoadsorption lower than 30 g of immunoglobulin/ml. Particulates were processed at 0 to 4°C as described by Wang et al. (1998) . Briefly, particulates were solubilized at 2% Triton X-100 and 0.4 to 0.5 mg protein/ml, and after 90 min in ice, they were centrifuged for 12 min at 20,000g max . Tracers (1  nM [ 3 H]Epb, 200 pM 125 I-Epb, 500 pM 125 I-Cntx, or 1 nM 125 I-Bgtx) were added to the supernatant and incubated for 16 to 18 h at 4°C. Duplicate aliquots containing 25 g of extracted protein were mixed, in the final volume of 0.20 ml, with the appropriate antibody, using 1, 3, and 6 l of each antibody. This corresponded to 0.2, 0.6, and 1.2 g of immunoglobulin for the polyclonal antibodies, or 1, 3, and 6 g of immunoglobulin for the monoclonal ␣6 antibody, and produced a complete saturation of receptor immunoadsorption for all antibodies (see Results) ( Fig. 5A ). The mixtures were rotated with protein A/protein G agarose (Santa Cruz Biochemicals) for 8 h at 4°C. Correction for nonspecific adsorption was obtained by incubating the largest input of the respective antibody with 10 M cytisine plus 100 M (Ϫ)-nicotine for Epb or Cntx tracers and with 1 M unlabeled Bgtx plus 100 M nicotine for the Bgtx tracer. The nonspecific adsorption was always less than 2% of total agarose gel radioactivity with Epb tracers (with typical "signal-to-noise" ratios better than 100 for ␣3 and ␣6 and better than 1000 for ␣4 and ␤2 subunits), but it represented up to 30% of total gel radioactivity with 125 I-Cntx or 125 I-Bgtx tracer. The assays were terminated by dilution and sedimentation for 1 min at 1000g max followed by three resedimentations Fig. 1 . A comparison of lever-pressing activity in self-administration of nicotine or saline by rats over 18 days after habituation. Six animals were compared in each group. The brains of these animals were used in receptor assays shown in Fig. 3 . The mean numbers of lever presses per day (Ϯ S.E.M.) for the four data sets were analyzed by two-way analysis of variance (see Materials and Methods) . The difference between treatments was highly significant (F ϭ 51.6, p Ͻ 0.001), whereas the difference across the time points (F ϭ 1.34, p ϭ 0.164) or that in interaction between the type of treatment and the length of treatment (F ϭ 1.29, p ϭ 0.087) was not significant. The data were further compared in Scheffe's tests, and the differences significant at Ͼ95% confidence between the nicotine self-administering set and all other sets are indicated in the graph by asterisks. 3 H]Epb-labeled pellets were dispersed in 2% sodium dodecyl sulfate/0.01 M Tris-HCl, pH 8.8, before liquid scintillation counting.
Up-Regulation of Brain nAChR Subunits by
Immunoblotting of Nicotinic Receptors. The washed particulates were solubilized and extracted at 4°C in radioimmunoprecipitation assay buffer (Santa Cruz Biochemicals), the extracts were cleared (30 min at 30,000g max and 4°C), and the supernatants were mixed with an equal volume of a denaturation buffer (Bio-Rad, Hercules, CA), heated for 30 min at 98°C, and then resedimented as described above. Aliquots of the supernatant were electrophoresed in polyacrylamide gels, electroeluted onto nitrocellulose, and saturated with a blotting buffer (Blotto B; Bio-Rad). The membranes were then incubated for 16 h at 4°C in 0.14 M NaCl/10 mM Tris-HCl, pH 7.4, containing 2 g/ml of one of the rabbit polyclonal antibodies (Santa Cruz Biochemicals) to human ␣3, ␣4, or ␤2 nAChR subunits or 6 g/ml of the mouse monoclonal antibody to human ␣6 subunit. After washing and a 90-min exposure to goat anti-rabbit or anti-mouse immunoglobulins coupled to horseradish peroxidase (1:2000 to 1:5000 dilution) and final washing, membranes were exposed to Luminol bioluminescent reagent (Santa Cruz Biochemicals), apposed to Kodak BR Biomax film (Eastman Kodak, Rochester, NY), and the negatives were scanned.
Data Analysis. To analyze the frequency of nicotine and saline self-administration, the mean number of lever presses per day were compared by two-way analysis of variance, followed where appropriate by Scheffe's test, using SPSS statistical software, version 11.0 (SPSS Inc., Chicago, IL). Evaluation of immunoadsorption with multiple data-point profiles was done by nonlinear fitting to MichaelisMenten equation (Parker and Waud, 1971 ) followed by t tests on means of the binding parameters. Grain density in scans of Western blot profiles was evaluated using OptiQuant software (PerkinElmer Life and Analytical Sciences). The means of receptor binding parameters were compared in two-tailed Student's or Dunnett's t tests (Zar, 1984) . The quantitative comparisons on six competition points (see The Epibatidine Binding Assay section under Materials and Methods) were done with least-square Scatchard fits, because nonlinear Scatchard fitting with only six concentration points tends to result in large variations; the least-squares Scatchard linearization using analytical second derivatives is routine in similar evaluations (Segel, 1974; Marks et al., 1998) . The nonlinear curve fits generated by either the LIGAND program (Munson and Rodbard, 1980) or the curve-fitting facility of the SigmaPlot program (version 8.0; SPSS Inc.) were used to check for multiple components in competition profiles with eight or more concentration points. Hill slopes (n H ) were calculated using Scatchard estimates of B max in the logarithmic Hill equation (Segel, 1974) . Sequence comparisons were done in FASTA programs (Pearson, 2000) .
Results
Active and Inactive Lever Presses during Nicotine or Saline Self-Administration. The self-administration profiles for the two groups of rats used for receptor assays is shown in Fig. 1 . The number of active lever presses resulting in nicotine self-administration was significantly greater than for any other group from the 6th day of treatment and remained at 40 to 50 active lever presses per day through day 18. In contrast, the number of active lever presses for control rats self-administering saline varied between 20 and 25 presses per day. There was a highly significant difference in active lever presses between treatment groups (analysis of variance, p Ͻ 0.001) (Fig. 1) , and analysis by day from the 6th day on also showed a significant effect of nicotine (p value range of 0.001 to 0.05) (Fig. 1) . The number of inactive lever presses, which had no programmed consequence, was similar for both nicotine and saline self-administration and never exceeded 15 per day. Analyses showed no difference in inactive lever presses by treatment group or between active lever presses in the saline group and inactive lever presses in either treatment group (see legend to Fig. 1) .
Homogeneity of High-Affinity Epibatidine Binding in Discrete Rat Forebrain Areas. Previous reports indicated the presence of two distinct high-affinity (in the K d range of 10-400 pM) components of epibatidine binding in particulates from whole rat forebrain (Houghtling et al., 1995) but not in a number of forebrain areas of the mouse (Marks et al., 1998) . Differences related to multiple highaffinity components of agonist binding, if present in discrete brain areas of the rat, may confound comparisons of receptor numbers between brain areas or between treatment groups.
The saturation binding of epibatidine (in the range of 10-1000 pM) to particulates from several rat brain areas is shown for three rat forebrain areas in Table 1 (Munson and Rodbard, 1980) or the curve-fitting facility of the SPSS SigmaPlot program] in more than one component. With particulates from several brain areas, solubilization at 2% Triton X-100 and assay at 0.1 to 0.5% final of the detergent lowered the binding affinity of [
3 H]epibatidine uniformly approximately 3-fold without a significant change of B max ; data for rat thalamic extract are shown in Fig. 2 . As would be expected from the lack of change in the binding capacity, the solubilization also did not result in additional binding components discernible in the 10 to 1000 pM range. The observed change in K d is not major and should relate to a less compact conformation of the binding site. The robust preservation of nAChR binding capacity is of critical importance for appro- The binding parameters are Scatchard estimates from three saturation assays for each brain region and ligand (using eight different concentrations ranging from 10 to 1000 pM of either radionuclide), shown as means Ϯ S.E.M. In all cases, fitting to a single specific component in the LIGAND program (Munson and Rodbard, 1980) produced lower residual variance and much higher F values in F-runs testing, relative to fits assuming two specific binding components. At 1000 pM, the nonspecific binding ͓defined using 30 M (Ϫ)-nicotine͔ did not exceed 12% of the total binding for particulates from any brain region (also see Fig. 2 ). priate immunoassays of the solubilized receptor. It is of interest to note that the number of epibatidine binding sites in the mouse brain was similar to those found in the rat brain in two regions (data not shown), hypothalamus and hippocampus, but it was 40% lower than the rat number for thalamus/ subthalamus (Fig. 2) and was approximately 75% lower for the mouse parietal cortex [K d ϭ 34.1 Ϯ 2.7 pM and B max of only 10.4 Ϯ 1.4 fmol/mg protein (n ϭ 3) compared with 38.1 fmol/mg protein in the rat parietal cortex] (Table 1) . By examining the particulates from three forebrain areas (hypothalamus, parietal cortex, and thalamus/subthalamus) of control rats and from two areas (parietal cortex and thalamus/subthalamus) of nicotine-self administering rats, however, we were unable to find significant area-related or treatment-dependent differences in the saturation binding K d values for either 125 I-epibatidine or [ 3 H]epibatidine within the concentration range of 10 to 1000 pM (Table 1) . Furthermore, the affinity of saturation binding obtained for both radioligands did not differ significantly over the range of 10 to 1000 pM with particulates from any of the areas. The Hill slopes (n H ), calculated using the logarithmic Hill equation (Segel, 1974) , were in the range of 0.8 to 1.2 ( (Whiteaker et al., 1998) .
Estimates of epibatidine binding parameters obtained in saturation assays using 125 I-Epb and [ 3 H]Epb (Table 1) were in good agreement with those obtained in competition of 50 pM 125 I-Epb by unlabeled Epb at six concentrations in the range of 10 to 1000 pM ( Fig. 3 and Table 2 ). This is to be expected, because only one binding component was detected with either radioligand within the concentration range used. Extension of the Epb concentration range showed a small ␣7 site-related low-affinity component (K d ϭ 7-12 nM) that could be eliminated by 1 M ␣-bungarotoxin  results not shown). Using nonlinear Scatchard fitting (Munson and Rodbard, 1980) , no significant second component could be detected in any of the competition profiles in the range of 10 to 1000 pM of competing Epb. In all cases, the Hill slopes (n H ) for the competition studies were in the range of 0.8 to 1.2 (data not shown), again indicating the absence of subpopulations with significantly different affinities. (Munson and Rodbard, 1980) nonlinear Scatchard fitting in both cases rejected two-component models. The nonspecific binding at 1000 pM [Up-Regulation of Epibatidine Binding Sites by LongTerm Self-Administration of Nicotine. Increased numbers of Epb-labeled nicotinic receptors compared with paired controls were found in animals continually self-administering nicotine in all brain areas examined ( Fig. 3 and Table 2 ). The ranges of B max increase relative to controls showed no overlap in 8 of 11 areas examined. Studies of an additional six pairs of animals, self-administering the same dose of nicotine, showed a substantial and uniform increase in the number of Epb sites in all areas examined (i.e., thalamus/ subthalamus, hypothalamus, parietal cortex, and VTA/SN; data not shown). Table 2 shows that the largest increase of 125 I-Epb sites was found with particulates from the region containing the nucleus tractus solitarii area and from VTA/SN, followed by those from nucleus accumbens. A large increase also was present in thalamus/subthalamus, parietal cortex, hypothalamus and amygdala. A significant but smaller increase was evident in piriform cortex, caudate/putamen, and hippocampus ( Fig. 3 and Table 2 ). A small yet significant increase was also found with particulates from cerebellar cortex. These increases were routinely confirmed by saturation assays using concentrations of [ 3 H]Epb in the range of 10 to 1000 pM; the results for thalamus/subthalamus and parietal cortex are shown in Table 1 .
Cytisine Sensitivity of the Binding of Either Epibatidine or ␣-Conotoxin MII Is Decreased in Rats Continually self-administering nicotine. The ␣3*, ␣4*, and ␣6* nicotinic receptors all bind epibatidine with high affinity (Kaiser and Wonnacott, 2000; Zoli et al., 2002) but differ in the sensitivity of Epb binding to cytisine. This nicotinic agonist strongly competes Epb binding to ␣4*␤2* sites (Flores et al., 1997) . However, cytisine is a much weaker competitor of Epb binding to nAChRs containing ␣ subunits structurally similar to rat ␣6, including chick ␣6* receptors (Vailati et al., 1999 ) (77% sequence identity with rat ␣6 subunit) and rat ␣3* receptors (Xiao et al., 1998 ) (66% sequence identity with rat ␣6 subunit). Cytisine was also shown to differentiate Epb binding sites in areas of mouse brain (Marks et al., 1998) , which may to some degree be related to the content of ␣6* Fig. 3 . Scatchard binding parameters for 125 I-epibatidine binding to particulates from brain areas of rats continually self-administering (Ϫ)-nicotine (ϳ1.5 mg/kg/day) and the corresponding control rats. The results are averages of separate competition assays on six individual animals for each paradigm and brain area, competing 50 pM of the radioligand with six different concentrations (in the range of 10 -1000 pM) of nonlabeled Epb. The K d range was 21 to 43 pM. In t tests, the only significant K d value difference from control rats was found for VTA/SN area. The Hill slope coefficients (n H ) taken from Scatchard B max values ranged from 0.85 to 1.25 (data not shown). *, significance versus the corresponding control mean B max in t tests (*, p Ͻ 0.05; **, p Ͻ 0.01). Very similar B max values were observed in assays using [ 3 H]epibatidine (see Table 1 ). For other details see Materials and Methods. NAcc, nucleus accumbens; NTSA, area of the nucleus tractus solitarii; CPu, the caudate/putamen area; Par, the parietal cortex; Pir, the piriform/entorhinal cortex; Thal, thalamus/subthalamus; Hipp, hippocampus; Hyp, hypothalamus; Amyg, amygdala; CRB, the cerebellar cortex. (Champtiaux et al., 2002) . As seen with four tissues in Table 3 , a significant increase in resistance to cytisine in rats continuously self-injecting nicotine was found especially for [ 3 H]Epb binding to particulates from nucleus accumbens and also from thalamus/subthalamus and parietal cortex. The increase over control rats was especially pronounced at the highest molarity of cytisine tested. Moreover, the resistance apparently increased with the molarity of cytisine. The linear regression coefficient (r 2 ) for cytisine concentration versus Epb binding was 0.93 to 0.98 (p ϭ 0.05-0.001) with particulates from the above areas. A lesser increase in resistance of [ 3 H]Epb binding to cytisine and a lack of regression were found with hippocampal particulates.
The binding of the ␣3/␣6 subunit-selective nicotinic antagonist 125 I-␣-conotoxin MII as displaced by cytisine (Whiteaker et al., 2000a) was also compared in four brain areas from rats continually self-administering nicotine versus saline. As expected, this binding was much lower than that of epibatidine but showed a large up-regulation after long-term nicotine self-administration, especially in nucleus accumbens and thalamus/subthalamus (Table 4 ). The sensitivity of 125 ICntx binding to cytisine dramatically decreased in nucleus accumbens and thalamic/subthalamic particulates of animals self-administering nicotine, in which the displacement relative to control decreased steadily with increasing molarity of cytisine. This also was present with particulates from parietal cortex. In contrast, the decline in cytisine sensitivity was significant for hippocampal particulates only at the highest concentration of cytisine (Table 4) . However, the linear regression was significant (r 2 Ͼ 0.9, p Ͻ 0.05) in all cases. A recent autoradiographic study indicated a high density of ␣-conotoxin MII binding sites in mouse dorsal thalamic areas, which includes the habenular nuclei, as well as a moderate density in the subthalamic region (Champtiaux et al., 2002 ). Because we also found a relatively high density of nAChRs in rat thalamus, we compared the binding of 125 ICntx in three thalamic subsections of rat and mouse. As seen in Table 5 , the specific binding of this neurotoxin was consistently higher in rat thalamic areas compared with those of the mouse, especially in the subthalamic area. In both species, the Cntx binding to particulates from dorsal thalamic area was significantly larger than that in the other two thalamic areas.
Characterization of the Subunit Composition of nAChRs Using Antibodies Specific for the Major Subunits. The identities of subunits as well as the differences in subunit abundance between the long-term nicotine versus saline self-administration groups were verified by immunoblotting. Western blots prepared with extracts of thalamic particulates using the rabbit polyclonal antibodies to human ␣4 or ␤2 subunit or the mouse monoclonal antibody to human ␣6 subunit showed a single major component linearly increasing in quantity with increase in receptor protein (r 2 Ͼ 0.95, p Ͻ 0.05 in all cases) (Fig. 4) . As expected, the immunoreactivity was considerably greater in animals self-administering nicotine than in those receiving saline (Fig. 4) . For low-abundance proteins such as ␣3 or ␣6 nAChR subunits, only semiquantitative comparisons could be made by immunoblotting; however, the binding of high-affinity radioligands to nAChRs, followed by immunoadsorption, requires much lower protein input yet provides a precise quantification for all subunits.
Published studies have demonstrated the specificity of monoclonal ␣6 antibody by showing that neither ␣3␤2 nor ␣4␤2 nAChRs expressed in oocytes were immunoadsorbed (Kuryatov et al., 2000) . In contrast, large amounts of ␣6␤2 were immunoadsorbed by ␣6 monoclonal antibody, and none were immunoadsorbed by antisera to ␣3 or ␣4 subunits. In addition, the rat ␣3 subunit expressed in HEK-293 cells as ␣3␤4 nAChRs (Xiao et al., 1998) was detected by the polyclonal ␣3 antibody at 118 Ϯ 4 fmol 125 I-epibatidine immunoadsorbed per mg input protein (n ϭ 6), whereas the monoclonal ␣6 antibody only immunoadsorbed 4.1 Ϯ 0.5% of this amount of radioactivity. Moreover, saturating quantities of the polyclonal ␣4, ␣7, and ␤2 antibodies immunoadsorbed 3.6 Ϯ 0.15, 1.7 Ϯ 0.4, and 5.8 Ϯ 1.0%, respectively, of the above ␣3 antibody immunoreactivity (n ϭ 3). The polyclonal antibody to human ␣7 subunit immunoadsorbed 12 Ϯ 2.4 fmol 125 I-Bgtx/mg protein of rat thalamus; virtually no immunoadsorption ensued upon 125 I-Bgtx-labeled receptor incubation with saturating amounts of the ␣4, ␣6, and ␤2 antibodies. These results and the previous report (Kuryatov I-epibatidine binding to particulates from brain areas of rats continuously self-administering nicotine compared with the corresponding control rats
Particulates from six rats self-administering nicotine and six paired control rats were individually assayed for competition of the binding of 50 pM 125 I-epibatidine by 0, 10, 30, 100, 300, and 1000 pM of unlabeled Epb and by 30 M (Ϫ)-nicotine (used to define the nonspecific binding). The parameters are estimates from Scatchard plots (bound/free versus bound). Because the particulate protein input was only 25 g/ml, the highest bound/free ratios were lower than 0.25 in all profiles, and there were no significant effects on the apparent affinity caused by ligand depletion seen with ͓ 3 H͔nAChR ligands because of their low specific activity (Houghtling et al., 1995; Marks et al., 1998) . The mean percentage increase values for nicotine-treated over control rats are followed by levels of significance in t tests (*, p Ͻ 0.05, **, p Ͻ 0.01). The Scatchard plots are presented graphically in Fig. 3 . The slopes of logarithmic Hill plots (n H ) were in the range of 0.8 to 1.2, indicating the absence of multiple affinity components in the binding over the Epb molarity range used. , 2000) are in accord, showing strong selectivity of the antibodies used to detect the respective subunits. As shown in Fig. 5A for rat thalamic [ 3 H]Epb-labeled receptors reacting with four nAChR subunit-specific antibodies, the immunoadsorption of Epb binding to Triton X-100-solubilized receptor was saturated within the range of antibody input used in the assays. As expected, the immunoadsorbed ␤2 binding was by far the most abundant in all brain areas examined (Figs. 5 and 6) followed by ␣4 binding. The Epb binding ratios for immunoadsorbed ␤2/␣4 were 3 to 3.5:1 with rabbit polyclonal anti-human antibodies. Using the monoclonal rat anti-rat antibodies, the ␤2/␣4 ratios were 2.5 to 3 (data not shown). The immunoadsorption of [ 3 H]Epb directed by the mouse monoclonal antibody to human ␣6 receptor was approximately four to six times less than that produced by either rabbit polyclonal (Fig. 5B ) or mouse monoclonal (not shown) antibody to the human ␣4 subunit. The immunoadsorption induced by rabbit polyclonal antibody to human ␣3 subunit was lower than ␣6 immunoadsorption in thalamus (Figs. 5B and 6 ) and three other areas tested (Fig. 6 ).
The Abundance of ␣3, ␣4, ␣6, and ␤2 Subunits Compared by Immunoadsorption of Radiolabeled Receptors. Figure 6 shows the immunoadsorption of 125 I-Epblabeled receptors from four brain areas of long-term nicotine versus saline self-administering rats using antibodies against ␣3, ␣4, ␣6, and ␤2 nAChR subunits. Radiolabeled ␣3* subunit nAChRs were immunoadsorbed at levels lower than 2 fmol Epb/mg protein in all areas examined. Nicotine selfadministration was associated with up-regulation of these ␣3* receptors only in VTA/SN and nucleus accumbens. In addition to these areas, the binding to ␣4 subunit-containing AChRs was significantly increased in thalamus/subthalamus. The immunoadsorbed binding corresponding to nAChRs containing the ␤2 subunit was strongly and significantly elevated in all areas. Finally, the immunoadsorbed ␣6 subunit, labeled by either 125 I-Epb or 125 I-Cntx, was significantly up-regulated in all areas.
The binding ratios of immunoadsorbed nAChR subunits from nicotine compared with saline self-administering rats are shown in Fig. 7 . From the preceding data (Fig. 6) , the binding ratio of nAChR ␣6 subunit was strongly increased in I-Cntx to particulates (total and nonspecific; n ϭ 6 for each) was performed as described in thalamus/subthalamus, caudate/putamen, and nucleus accumbens of nicotine self-administering rats (Fig. 7) . In all four areas, this ratio was consistently higher (at least at the 95% confidence level in Dunnett's t test) than the ratio for the ␣4 subunit. The mean ratios of ␣6 subunits were also significantly greater than those for ␤2 in thalamus/subthalamus and caudate/putamen (Fig. 7) . In these two areas, the ratio also was consistently and significantly greater for the ␤2 compared with the ␣4 subunit, indicating a relatively greater change of the ␤2 subunit during nicotine self-administration.
Discussion
The results of this study demonstrate consistent up-regulation of nAChRs in multiple regions of rat brain during long-term self-administration of nicotine. This is in keeping with both the earliest (Schwartz and Kellar, 1983) and the most recent (Mugnaini et al., 2002) findings on the regulation of nAChRs by nicotine in rat brain, as well as with extensive studies in the mouse (Pauly et al., 1996; Whiteaker et al., 2000b) .
The increase of nAChRs by long-term nicotine administration in the rat may strongly depend on the dosage and the mode of delivery of the alkaloid and on the rat strain used. Thus, intermittent subcutaneous application of nicotine in Sprague-Dawley rat at 4 mg/kg/day produced only 15 to 25% increase of [ 3 H]cytisine binding (Jacobs et al., 2002) . In Wistar rats, continuous infusion of nicotine at 3 mg/kg/day produced an average 46% increase of [
3 H]nicotine binding in the majority of brain areas examined (Mugnaini et al., 2002) . In the present study, Lewis rats (used because of their propensity to self-administer nicotine) continually self-administering nicotine at approximately 1.5 mg/kg/day showed an average 63% increase of 125 I-epibatidine binding in the brain areas examined. Representative immunoblots of rat thalamic ␣4, ␣6, and ␤2 subunits from rats continually self-administering nicotine versus saline (control). Tissue from three control or nicotine self-administering animals was pooled for the assay. After electrophoretic separation and blotting, the transfers were reacted with the corresponding antibodies (see Materials and Methods) . Protein input per lane (in g) is indicated above the corresponding profiles. Molecular masses, from covalently dyed standards, were approximately 60 kDa for ␣4 and 55 kDa for ␣6 and ␤2. No other major bands were present near the indicated molecular mass range of the corresponding subunit bands. As seen in graphs on the right, grain densities followed a linear (r 2 Ͼ 0.95 in all cases) change with amount of input protein for each subunit and indicated consistently greater immunoreactivity in blots from rats continually self-administering nicotine. 
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The pronounced ability of nicotine to release dopamine during long-term in vivo treatment (Carboni et al., 2000) may be related to a disproportionate increase of specific nAChR subunits. In nAChRs that are located in brain areas possessing abundant dopaminergic terminals, such as nucleus accumbens (Champtiaux et al., 2003) , these could be the ␣6* receptors. We indeed found the largest relative increase of ␣6* in two areas rich in cell bodies and terminals releasing this catecholamine (VTA/SN and nucleus accumbens). In the same areas, we also found a strong and concordant up-regulation of the binding of ␣-conotoxin MII, a partial agonist of dopamine release (Grady et al., 2002) and an ␣6*-selective nAChR ligand. The amount of immunoreactive ␣3* receptors detected in particulates from these areas was much lower than that of ␣6* receptors. Most of the dopaminergic neurons in areas that in our experiments showed strong up-regulation of ␣6* ligand binding and immunoreactivity are known to express relatively high levels of the ␣6* nAChRs (Champtiaux et al., 2003) .
Our experiments consistently detected a single high-affinity binding component for epibatidine in the rat brain areas studied. This is predictable from the similarity of the affinity ranges for epibatidine at ␣3*, ␣4*, ␣6* (Parker et al., 1998a; Xiao et al., 1998; Zoli et al., 2002; Champtiaux et al., 2003) , and even chimeric ␣6␣4* receptors (Evans et al., 2003) , which would produce an apparent integration of small differences in affinity. A single high-affinity component of Epb binding was found in mouse brain (Marks et al., 1998) , whereas the same study showed large sensitivity differentials across brain areas for cytisine, an agonist preferring ␣4* AChRs (Flores et al., 1997) and less active at ␤2* (Houlihan et al., 2001) receptors. Two high-affinity binding components for Epb in rat forebrain were found by Houghtling et al. (1995) ; however, they used conditions of homogenization and assay that were quite different from those used by Marks et al. (1998) and in the present study.
We found increased resistance to cytisine for either [ 3 H]epibatidine or 125 I-␣-conotoxin MII binding in rats continually self-administering nicotine. This was present not Fig. 6 . Immunoadsorption of 125 I-epibatidine-or 125 I-␣-conotoxin MII-labeled nicotinic receptors from four brain areas of control rats and of rats continually self-administering nicotine. Polyclonal rabbit antibodies to human ␣3, ␣4, and ␤2 nicotinic subunits and monoclonal mouse antibody to human ␣6 nicotinic receptor subunit were used as detailed under Materials and Methods. The results are the average maximum binding estimates using single-component hyperbolic fitting (Parker and Waud, 1971 ) on data from six control and six nicotine-injected animals. The mean maximum binding values were compared in t tests (significance levels: *, p Ͻ 0.05; **, p Ͻ 0.01). Thal, thalamus/subthalamus; NAcc, nucleus accumbens; CPu, the caudate/putamen area. I-Epb binding that reacted with antibodies to the indicated nAChR subunits. The mean ratios for control and nicotine self-administering animals in each area were compared using Dunnett's t test after positive analysis of variance (significance levels: *, p Ͻ 0.05; **, p Ͻ 0.01 for the difference between the mean ␣6 or ␤2 and ␣4 ratio; &, p Ͻ 0.05 for the difference between the mean ␣6 and ␤2 ratio). Thal, thalamus/subthalamus; NAcc, nucleus accumbens; CPu, the caudate/putamen area. only in the dopaminergically active nucleus accumbens but also in the parietal cortex and hippocampus. Taken from a relatively low sensitivity of ␤2* nAChRs to cytisine (Houlihan et al., 2001) , this nAChR agonist might also be less active in competing Epb binding to AChRs containing two or more ␤2 subunits. Surface nAChRs containing three ␤2 subunits are preferentially increased by nicotine in cells expressing cloned ␣4␤2 receptors (Nelson et al., 2003) . Such nAChRs could accumulate in rats continually self-administering nicotine. By analogy with its poor labeling of cell surface ␣4 2 ␤2 3 nAChRs expressed in HEK-293 cells (Zhang and Steinbach, 2003) , cytisine also may not readily access a fraction of brain particulate nAChRs. The nAChRs not readily available for cytisine binding could be the more membrane-immersed or aggregated receptors, accumulating in animals self-administering nicotine because of channel desensitization or other factors. The structure of cytisine is rigid and more conformationally restricted than that of epibatidine (Barlow and Johnson, 1989; Wei et al., 2003) . Consequently, cytisine may not access the binding sites of closely grouped or partially compartmentalized nAChRs. This could produce multiple components of competition with the binding of epibatidine (Marks et al., 1998) and result in partial agonism (Houlihan et al., 2001) .
Up-regulation of surface nAChRs caused by long-term nicotine treatment could be related to desensitization, as shown for ␣4␤2 receptors in oocytes (Fenster et al., 1999) . Desensitization of nAChRs may be associated with a partial sequestration or compartmentalization, which is found with some rhodopsin-like receptors (Beaumont et al., 1998; Parker et al., 2002) . The large second intracellular domain found in all sequenced ␣4 subunits (approximately 270 amino acid residues), being twice the size of the corresponding domain of any other nAChR subunit, is likely to induce an asymmetry in assembled holoreceptor pentamers. This segment also contains an alternating-cysteine CXCXC sequence (X ϭ amino acid other than Cys), not present in any other nAChR subunit, which can be expected to interact with chaperones and assist the association of ␣4* nAChRs with intracellular membranes. The above features are likely to induce a larger compartmentalization of ␣4 subunits relative to other ␣ subunits.
Surface ␣4* receptors are difficult to maintain in cell lines at 37°C, apparently because of a strong inward vectorial drive under physiological conditions, but can be maintained below 37°C (Cooper et al., 1999) . Recent work shows that at 29°C (i.e., below the expected phase transition of major membrane phospholipids) (Martin and MacDonald, 1976) all nicotinic receptor subunits can be surface-expressed and upregulated by nicotine in cell lines (Nelson et al., 2003; J. M. Lindstrom, unpublished observations) . Also, cell-surface ␣4 2 ␤2 3 receptors are up-regulated by nicotine treatment more than ␣4 3 ␤2 2 receptors (Nelson et al., 2003) . In contrast, ␣3* receptors are well-retained in plasma membrane at 37°C and have been stably expressed by many researchers. The 65% sequence homology of rat ␣6 and ␣3 subunits [for sequences, see the Swiss-Protein files P43143 (rat ␣6) and P04757 (rat ␣3)] indicates that surface ␣6* receptors are also likely to be stably exteriorized at 37°C, as has indeed been found in HEK-293 cells (Evans et al., 2003) . The above studies are all compatible with our finding of a disproportionate up-regulation, relative to ␣4* receptors, of ␣6* nAChRs, and to some degree also of ␤2* nAChRs, in rats continually selfadministering nicotine.
Because long-term nicotine treatment can up-regulate ␣3* receptors in a cell line (Wang et al., 1998) , the structurally similar ␣6* receptors are likely to accumulate during nicotine treatment, as found in our experiments. The surface retention of nAChRs may be promoted by nicotine-induced depolymerization of F-actin (Cheek and Burgoyne, 1987) . A decrease in microfilament proteins induced by long-term nicotine administration (observed in ventral tegmentum by Sbarbati et al., 2002) may also improve the surface retention of nAChRs. Nicotine also promotes the transfer of phospholipid-interacting annexins into the filament matrix (Sagot et al., 1997) , which might increase surface embedding of nicotinic and other receptors. An accumulation of receptor-organizing proteins akin to the neuromuscular synapse proteins rapsyn or agrin (which slow the turnover of the muscle nicotinic receptor) (Phillips et al., 1997) could increase the surface retention of nAChRs. However, scaffoldings of this type have thus far not been defined in the brain.
Up-regulation of nAChRs during long-term nicotine treatment could be related to the aforementioned nicotine-induced decrease of receptor interaction with the microfilament/cytoskeletal system. The up-regulation of nAChRs containing specific subunits, and in particular the ␣4* receptors, could be counteracted by sequestration and/or compartmentalization. For a significant fraction of nAChRs, micromechanical changes related to altered cytoskeletal interactions may contribute to a decrease in receptor-channel sensitivity to agonists without a large change in the binding affinity, a state usually identified as desensitization. The extent, duration, and occurrence of desensitization could, however, differ according to the subunit composition of nAChRs. By analogy with ␣3* receptors (Fenster et al., 1999) , the ␣6* receptors could be more resistant to desensitization by nicotine and presumably easier to recover. The observed larger up-regulation of ␣6* nAChRs relative to ␣4* receptors in rats continually self-administering nicotine may help maintain, or even facilitate, the release of neurotransmitters, especially dopamine.
